The 24th World Pharmaceutical Ingredients China Exhibition & The 19th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition
"The 24th World Pharmaceutical Ingredients China Exhibition" & "The 19th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition" (CPHI & PMEC China 2026) will be grandly held from June 16–18 at the Shanghai New International Expo Centre. We sincerely invite you to visit our booth! W1E26 — See you there!
CPHI is a premier global pharmaceutical industry event originating from Europe with over 30 years of history. Its series of exhibitions span Europe, China, Korea, India, Japan, Southeast Asia, the Middle East, and North America. As a bellwether for the pharmaceutical industry in Asia and beyond, CPHI & PMEC China has been deeply cultivated for over two decades, covering the entire industry chain including raw materials and excipients, CRO & CMO, biopharmaceuticals, packaging, and laboratories. From June 16–18, 2026, the 24th edition will make a powerful landing at the Shanghai New International Expo Centre, bringing together 3,600 exhibitors across 240,000 square meters and expecting to attract 110,000 professional visitors from over 150 countries and regions, creating a full-ecosystem exchange platform covering R&D, production, and supply chain.
From June 16–18, 2026, Poly Pharm will exhibit a wide range of products and services (Booth No.: W1E26). We sincerely invite friends from all sides to visit our booth for discussions and guidance!
Anhui Poly Pharm Co., Ltd., founded in 2018, is located in the Anqing National High-tech Industrial Development Zone. It is a professional supplier of active pharmaceutical ingredients, providing high-quality specialty raw materials through chemical synthesis and biosynthesis to the global pharmaceutical, healthcare, and skincare industries.
Anhui Poly Pharm boasts a strong and efficient R&D and production team, is equipped with modern production facilities, and has established a strict cGMP quality system for high-end APIs in Europe and the United States, as well as a high-standard EHS system. While providing customers with high-quality APIs and intermediates, it also offers CDMO services, process technology upgrades, and more. The company currently has 3 API production workshops compliant with European, American, and Chinese GMP standards, 10 production lines, and 357 multi-functional pieces of equipment.
Leveraging strong R&D capabilities and technology transformation capabilities, the company has completed the commercial R&D and production of a series of products, including contrast agents (gadoterate meglumine, gadoteridol, gadobutrol, iomeprol, iopromide, ioversol, iopamidol, iodixanol, etc.), synthetic biology products (semaglutide, ectoine, salidroside), antitumor drugs (cyclophosphamide), other APIs (magnesium hydroxide, apremilast, crisaborole, voriconazole, memantine hydrochloride), and other pharmaceutical excipients (DOTA, SNAC, sodium sulfobutyl ether-β-cyclodextrin, calcium catelidol, cobiprostone calcium). Leveraging the global registration and compliance capabilities of the Poly Pharm Group, Anhui Primes has established an international registration system for its Boron [¹⁰B] Melphalan (BPA) API, with the U.S. DMF as the forerunner, becoming the first company in China to obtain an FDA Type II DMF number (044131) for a BPA API. The company focuses on high-end specialty APIs and innovative raw materials, with multiple products achieving domestic substitution and global exports, making it one of the most competitive API suppliers in the field of BNCT boron drugs.
